infliximab + tocilizumab

Infliximab + tocilizumab is a combination of two monoclonal antibody biologic drugs, each targeting distinct pro-inflammatory cytokines involved in autoimmune and inflammatory diseases. Infliximab is a chimeric monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha (TNF-α), thereby reducing inflammation associated with conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor (both soluble and membrane-bound forms), inhibiting IL-6-mediated signaling pathways implicated in rheumatoid arthritis and other inflammatory disorders. The combination of these agents may be considered for patients with refractory autoimmune or inflammatory diseases who have not responded adequately to monotherapy or conventional disease-modifying antirheumatic drugs (DMARDs). Both agents are administered via intravenous infusion under medical supervision due to risks including immunosuppression and increased infection susceptibility.